Jump to content

Drilldown: Medicines

Choose a table:


Medicines > routes: Oral & halflife : 11-15 hours'"`UNIQ--ref-00000842-QINU`"' or ~12 hours

Use the filters below to narrow your results.

generic:
None (1) · Duloxetine (1) · Irbesartan (1)
brand:
Avapro (1) · Belsomra (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1)
classes:
Antidepressant (1) · Anxiolytic (1) · Dual orexin receptor antagonist (DORA) (1) · SNRI (1) · the first approved (1) · [[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blocker (ARB)]] (1) · [[:Category:Antihypertensives|Antihypertensive]] (1)
mechanism:
Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · '"`UNIQ--vote-0000083E-QINU`"' CYP2C9 substrate; no clinically active metabolites. The IDNT trial established renoprotection in diabetic nephropathy independent of BP lowering, contributing to the ARB class indication in T2DM with proteinuria'"`UNIQ--ref-0000083F-QINU`"'. (1)
uses:
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) · '"`UNIQ--vote-00000840-QINU`"', '"`UNIQ--vote-00000841-QINU`"' (1)
starting dose:
None (1) · 10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) · 150 mg PO once daily; titrate to 300 mg if needed (1)
preparations:
None (1) · 5 mg, 10 mg, 15 mg, 20 mg tablets (1) · 75, 150, 300 mg tablets (1)
fda max:
None (1) · 20 mg/d (1) · 300 mg/d (1)
routes: (Click arrow to add another value)
onset:
BP effect within 1-2 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · ~30 min (1)
duration:
24 hours (1) · Chronic daily dosing (1) · ~7-8 hours (1)
halflife: (Click arrow to add another value)
bioavailability:
60-80% (oral; not significantly affected by food)'"`UNIQ--ref-00000843-QINU`"' (1) · ~50% (highly variable) (1) · ~82% (1)
pregnancy:
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-00000844-QINU`"' (1) · Category C (1) · Limited data; avoid (1)
legal:
Rx, Schedule IV (US) (1) · Rx-only (1) · [[USLegal:Prescription only|Rx-only]] in US (1)
Error in "where" parameter: the string "--" cannot be used within #cargo_query.

There are no results for this report.

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"